Kesler Norman & Wride LLC Makes New $379,000 Investment in Medpace Holdings, Inc. (NASDAQ:MEDP)

Kesler Norman & Wride LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,131 shares of the company’s stock, valued at approximately $379,000.

Other large investors have also added to or reduced their stakes in the company. Rise Advisors LLC bought a new stake in Medpace in the 1st quarter worth $27,000. Mather Group LLC. bought a new stake in Medpace in the 1st quarter worth $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace in the 1st quarter worth $31,000. J.Safra Asset Management Corp grew its holdings in Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after acquiring an additional 47 shares during the last quarter. Finally, DT Investment Partners LLC bought a new stake in Medpace in the 2nd quarter worth $41,000. Institutional investors own 77.98% of the company’s stock.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $338.16 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The stock has a market cap of $10.48 billion, a P/E ratio of 34.47, a price-to-earnings-growth ratio of 1.88 and a beta of 1.35. The firm has a 50-day moving average of $362.27 and a 200 day moving average of $386.78.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.54 by $0.21. The business had revenue of $528.10 million during the quarter, compared to analysts’ expectations of $528.41 million. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The business’s revenue for the quarter was up 14.6% compared to the same quarter last year. During the same period in the previous year, the company earned $1.93 earnings per share. Research analysts expect that Medpace Holdings, Inc. will post 11.66 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on MEDP shares. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and dropped their target price for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Guggenheim dropped their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Finally, TD Cowen dropped their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.00.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.